Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 13/20 | 1.00 |
| ▸ | PREP | P48147 | 9/20 | 1.00 |
| ▸ | DPP4 | P27487 | 15/20 | 0.74 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.74 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.74 |
| ▸ | DPP7 | Q9UHL4 | 12/20 | 0.63 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8249904 | 1.00 | FAP (1.00) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL8251368 | 0.86 | FAP (0.74) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL13347225 | 0.84 | FAP (0.73) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL8286524 | 0.84 | FAP (0.73) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL23876862 | 0.84 | FAP (0.72) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL18084196 | 0.83 | FAP (0.71) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL25890374 | 0.82 | DPP4 (0.72) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL8253893 | 0.81 | FAP (0.68) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL8251748 | 0.81 | FAP (0.68) | FAPPREPDPP4DPP8DPP9 | |
| SCHEMBL8286526 | 0.81 | DPP4 (0.73) | FAPPREPDPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280856-A1 | Fibroblast Activation Protein Inhibitor Compounds and Methods | GENENTECH, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080280856-A1 | Fibroblast Activation Protein Inhibitor Compounds and Methods | GENENTECH, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-7399869-B2 | N-blocked peptide proline boronate compounds; hyperproliferative disorders like cancer, neurodegeneration, cardiac hypertrophy, pain, migraine, neurotraumatic disease, cirrhosis, fibromatosis, and rheumatoid arthritis | GENENTECH, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399869-B2 | N-blocked peptide proline boronate compounds; hyperproliferative disorders like cancer, neurodegeneration, cardiac hypertrophy, pain, migraine, neurotraumatic disease, cirrhosis, fibromatosis, and rheumatoid arthritis | GENENTECH, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| WO-2006125227-A2 | FIBROBLAST ACTIVATION PROTEIN INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280856-A1 | Fibroblast Activation Protein Inhibitor Compounds and Methods | FAP, FIBP, FGFR1 | FAP 1/4885PREP 23/4885DPP4 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.